Cystic fibrosis: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 35: | Line 35: | ||
[[Gene therapy|Gene Therapy]] | [[Gene therapy|Gene Therapy]] | ||
[[Pharmacotherapy|Pharmacotherapy]] | [[Pharmacotherapy of Cystic Fibrosis|Pharmacotherapy]] | ||
[[Alternative Channel Therapy|Alternative Channel Therapy]] | [[Alternative Channel Therapy|Alternative Channel Therapy]] |
Revision as of 11:45, 8 November 2010
Cystic Fibrosis
Cystic Fibrosis is an autosomal recessive disease located on chromosome 7. Cystic Fibrosis is caused by a mutation to the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) channel. The most common mutation is ΔF508, accounting for 70% of mutations in the Caucasin UK population, in which the triplet code for the amino acid phenylalanine is deleted, disrupting Cl- transport. This mutation belongs to the Class II group of mutations causing Cystic Fibrosis.
Classes of CFTR Mutations
Class I: Premature Stop Codons
Class II: Abnormal Processing
Class III: Altered Regulation
Class IV: Conductance Defect
Class V: Reduced Protein Synthesis
Approaches to Treatment
Lung Function
Oral and Inhaled Antibotics
Pancreatic Function
Nutrional Regime